Tempus Partners with Daiichi Sankyo to Advance AI-Led Biomarker Discovery in ADC Clinical Development
Thursday, March 26, 2026
Tempus AI has announced a strategic collaboration with Daiichi Sankyo to support the development and differentiation of an antibody drug conjugate (ADC) programme in oncology using artificial intelligence.
Under the agreement, Daiichi Sankyo will utilise Tempus’ AI capabilities, including its multimodal foundation model PRISM2, which integrates pathology images with clinical data to generate diagnostic and predictive insights. The collaboration will combine Daiichi Sankyo’s clinical and preclinical data with Tempus’ real-world data to improve biomarker discovery and patient stratification.
Both companies will work together to develop proof-of-concept AI models aimed at optimising patient selection and increasing the likelihood of clinical success for the ADC programme. These models will be applied across Tempus’ oncology database to produce detailed response mapping, enabling more precise identification of suitable patient groups.
The collaboration also aims to support the benchmarking of control arms for future clinical trials, contributing to more targeted and efficient trial design.
The partnership focuses on strengthening the use of AI and data integration in oncology drug development to improve clinical outcomes.
Source: tempus.com
